BJCT-BIOJECT-needle less injection product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: geewiz who wrote (414)	12/14/1999 10:23:00 AM
From: geewiz	Read Replies (1) of 534

Wall Street Transcript; twst.com <<TWST: Do you feel that the success of the platform will create a pipeline of opportunities, translating that system into different ongoing partnerships and opportunities? Mr. O'Shea: Yes that's our vision. For instance, considering the DNA vaccine studies where our product is being used extensively, should the success continue when these products are approved, it wouldn't be an option for a clinician to use a needle and syringe, because thes products are being used exclusively with our delivery platform. For example, if the DNA malaria vaccine were approved, physicians would use the Bioject system; not the needle and syringe. Obviously, that would be of great benefit to the company. In addition, successful reports of Phase-I and Phase-II clinical trials will interest other companies in using our platform. Already word of mouth is spreading, and we are constantly increasing the number of clinical research sites.>> later,art

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next